This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hinshelwood, R. A. Articles by Clark, S. J. Search for Related Content PubMed PubMed Citation Articles by Hinshelwood, R. A. Articles by Clark, S. J.

Concordant Epigenetic Silencing of Transforming Growth Factor-β Signaling Pathway Genes Occurs Early in Breast Carcinogenesis

¹ Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia; ² Children's Medical Research Institute, Westmead, New South Wales, Australia; ³ Human Genetic Signatures, North Ryde, New South Wales, Australia; ⁴ ARC Special Research Centre for Functional and Applied Genomics, Institute for Molecular Bioscience, University of Queensland; ⁵ Eskitis Institute for Cell and Molecular Therapies, Griffith University, Brisbane, Queensland, Australia; and ⁶ The Roslin Institute, University of Edinburgh, Roslin, United Kingdom

Requests for reprints: Susan J. Clark, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, New South Wales 2010, Australia. Phone: 612-9295-8315; Fax: 612-9295-8316; E-mail: s.clark{at}garvan.org.au.

Human mammary epithelial cells (HMEC) grown under standard cell culture conditions enter a growth phase referred to as selection, but a subpopulation is able to escape from arrest and continue to proliferate. These cells, called post-selection or variant HMECs, may be derived from progenitor cells found in normal mammary epithelium that subsequently acquire premalignant lesions, including p16^INK4A promoter hypermethylation. Epigenetic silencing of tumor suppressor genes through DNA methylation and histone modification is an early event in tumorigenesis. A major challenge is to find genes or gene pathways that are commonly silenced to provide early epigenetic diagnostic and therapeutic cancer targets. To identify very early epigenetic events that occur in breast cancer, we used microarrays to screen for gene pathways that were suppressed in post-selection HMECs but reactivated after treatment with the demethylation agent 5-aza-2'-deoxycytidine. We found that several members of the transforming growth factor β (TGF-β) signaling pathway were consistently down-regulated in the post-selection HMEC populations, and this was associated with a marked decrease in Smad4 nuclear staining. Gene suppression was not associated with DNA methylation but with chromatin remodeling, involving a decrease in histone H3 lysine 27 trimethylation and an increase in histone H3 lysine 9 dimethylation and deacetylation. These results show for the first time that TGF-β2, its receptors TGF-βR1 and TGF-βR2, and activator thrombospondin-1 are concordantly suppressed early in breast carcinogenesis by histone modifications and indicate that the TGF-β signaling pathway is a novel target for gene activation by epigenetic therapy. [Cancer Res 2007;67(24):11517–27]

This article has been cited by other articles:

				L. Hambach, K.-W. Ling, J. Pool, Z. Aghai, E. Blokland, H. J. Tanke, J. A. Bruijn, H. Halfwerk, H. van Boven, B. Wieles, et al. Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy Blood, March 19, 2009; 113(12): 2715 - 2722. [Abstract] [Full Text] [PDF]

				Y. S. Kim, M. R. Young, G. Bobe, N. H. Colburn, and J. A. Milner Bioactive Food Components, Inflammatory Targets, and Cancer Prevention Cancer Prevention Research, March 1, 2009; 2(3): 200 - 208. [Abstract] [Full Text] [PDF]

				J.F. Leal, I. Ferrer, C. Blanco-Aparicio, J. Hernandez-Losa, S. Ramon y Cajal, A. Carnero, and M.E. LLeonart S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis Carcinogenesis, November 1, 2008; 29(11): 2089 - 2095. [Abstract] [Full Text] [PDF]